131 related articles for article (PubMed ID: 17634538)
1. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.
Sørensen NM; Byström P; Christensen IJ; Berglund A; Nielsen HJ; Brünner N; Glimelius B
Clin Cancer Res; 2007 Jul; 13(14):4117-22. PubMed ID: 17634538
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of predictive markers for patients with advanced colorectal cancer.
Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
[TBL] [Abstract][Full Text] [Related]
3. Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer.
Aldulaymi B; Christensen IJ; Sölétormos G; Jess P; Nielsen SE; Brünner N; Nielsen HJ
Anticancer Res; 2010 Jan; 30(1):233-7. PubMed ID: 20150641
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
[TBL] [Abstract][Full Text] [Related]
5. Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
Frederiksen C; Qvortrup C; Christensen IJ; Glimelius B; Berglund A; Jensen BV; Nielsen SE; Keldsen N; Nielsen HJ; Brünner N; Pfeiffer P
Ann Oncol; 2011 Feb; 22(2):369-75. PubMed ID: 20643864
[TBL] [Abstract][Full Text] [Related]
6. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
[TBL] [Abstract][Full Text] [Related]
7. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
8. High plasma TIMP-1 and serum CEA levels during combination chemotherapy for metastatic colorectal cancer are significantly associated with poor outcome.
Aldulaymi B; Byström P; Berglund A; Christensen IJ; Brünner N; Nielsen HJ; Glimelius B
Oncology; 2010; 79(1-2):144-9. PubMed ID: 21150229
[TBL] [Abstract][Full Text] [Related]
9. Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.
Christensen IJ; Brünner N; Dowell B; Davis G; Nielsen HJ; Newstead G; King D
Anticancer Res; 2015 Sep; 35(9):4935-41. PubMed ID: 26254391
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Akbulut H; Altuntas F; Akbulut KG; Ozturk G; Cindoruk M; Unal E; Icli F
Cytokine; 2002 Nov; 20(4):184-90. PubMed ID: 12543084
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
[TBL] [Abstract][Full Text] [Related]
12. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Hamaguchi T; Denda T; Kudo T; Sugimoto N; Ura T; Yamazaki K; Fujii H; Kajiwara T; Nakajima TE; Takahashi S; Otsu S; Komatsu Y; Nagashima F; Moriwaki T; Esaki T; Sato T; Itabashi M; Oki E; Sasaki T; Chiron M; Yoshino T
Cancer Sci; 2019 Nov; 110(11):3565-3572. PubMed ID: 31520559
[TBL] [Abstract][Full Text] [Related]
13. A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1.
Nielsen HJ; Christensen IJ; Brünner N
Scand J Gastroenterol; 2010; 45(2):200-7. PubMed ID: 20095885
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Ji SH; Park YS; Lee J; Lim DH; Park BB; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
Jpn J Clin Oncol; 2005 Apr; 35(4):214-7. PubMed ID: 15845571
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
[TBL] [Abstract][Full Text] [Related]
16. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine as third line therapy in patients with advanced colorectal cancer.
Gubanski M; Naucler G; Almerud A; Lideståhl A; Lind PA
Acta Oncol; 2005; 44(3):236-9. PubMed ID: 16076695
[TBL] [Abstract][Full Text] [Related]
18. The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer.
Grem JL; Steinberg SM; Chen AP; McAtee N; Cullen E; Hamilton JM; Allegra CJ
Oncol Rep; 1998; 5(3):559-67. PubMed ID: 9538153
[TBL] [Abstract][Full Text] [Related]
19. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced colorectal cancer with folinic acid and 5-fluorouracil in combination with cisplatinum.
Sagaster P; Essl R; Teich G; Fritz E; Wasilewski M; Umek H; Dünser E; Mascher H; Micksche M
Eur J Cancer; 1994; 30A(9):1250-4. PubMed ID: 7999407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
